Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | terminated | Phase 3 | 166 | Canadian Urologic Oncology GroupOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | terminated | Phase 2 / Phase 3 | 58 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 |
| clinicaltrials |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | terminated | Phase 3 | 172 | Saving Patients' Lives Medical B.V.INDUSTRY | 4 | Apr 28, 2026 | clinicaltrials |
| NCT04876651 | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | terminated | Phase 3 | 16 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | terminated | Phase 3 | 158 | CR-CSSS Champlain-Charles-Le MoyneOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | terminated | Phase 3 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | terminated | Phase 3 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 3 | 104 | Hinova Pharmaceuticals USA, Inc.INDUSTRY | 14 | Aug 19, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT00651326 | Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer(DART) | terminated | Phase 3 | 48 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04457245 | Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer(PSMA-dRT) | terminated | Phase 3 | 54 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02745587 | Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.(PROPER) | terminated | Phase 3 | 69 | University Hospital, GhentOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT00354432 | Soy Protein/Effexor Hormone Therapy for Prostate Cancer | terminated | Phase 3 | 120 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03532308 | Nutrition and Prostate Cancer | terminated | Phase 3 | 19 | Yale UniversityOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | terminated | Phase 3 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00058188 | Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation | terminated | Phase 3 | 53 | Northwestern UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00003645 | Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence | terminated | Phase 3 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00415246 | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer | terminated | Phase 3 | 100 | IpsenINDUSTRY | 8 | Nov 22, 2019 | clinicaltrials |
| NCT01313273 | Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients(POSEIDON) | terminated | Phase 3 | 3 | IpsenINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00544076 | ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer | terminated | Phase 3 | 110 | City of Hope Medical CenterOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer(COMET-2) | terminated | Phase 3 | 119 | ExelixisINDUSTRY | 5 | May 23, 2018 | clinicaltrials |
| NCT00003682 | Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 3 | 160 | UNICANCEROTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | terminated | Phase 3 | 63 | Christopher Sweeney, MBBSOTHER | 2 | May 26, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT00243646 | Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial | terminated | Phase 3 | 6 | Schiffler Cancer CenterOTHER | 1 | Apr 14, 2016 | clinicaltrials |
| NCT00024167 | Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | terminated | Phase 3 | 265 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 22, 2016 | clinicaltrials |
| NCT01603420 | External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | terminated | Phase 2 / Phase 3 | 2 | Proton Collaborative GroupNETWORK | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00215631 | Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer? | terminated | Phase 3 | 100 | Erasmus Medical CenterOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT00809458 | Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer | terminated | Phase 3 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 16, 2015 | clinicaltrials |
| NCT00581113 | Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases | terminated | Phase 3 | 8 | Virginia Commonwealth UniversityOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01242748 | A Degarelix Trial in Patients With Prostate Cancer | terminated | Phase 3 | 288 | Ferring PharmaceuticalsINDUSTRY | 13 | Jun 3, 2015 | clinicaltrials |
| NCT00949962 | Post-operative or Early Salvage XRT and ADT for High Risk PCa | terminated | Phase 3 | 87 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 4, 2014 | clinicaltrials |
| NCT00831233 | Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer | terminated | Phase 3 | 42 | Ferring PharmaceuticalsINDUSTRY | 3 | Nov 11, 2013 | clinicaltrials |
| NCT00005075 | Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer | terminated | Phase 3 | — | EDAP TechnomedINDUSTRY | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00005073 | Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms | terminated | Phase 3 | 544 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00332280 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | terminated | Phase 2 / Phase 3 | 67 | Auron Healthcare GmbHINDUSTRY | 2 | Mar 20, 2013 | clinicaltrials |
| NCT00014586 | Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer | terminated | Phase 3 | 110 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00626548 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer(ENTHUSE M0) | terminated | Phase 3 | 2,577 | AstraZenecaINDUSTRY | 39 | Sep 3, 2012 | clinicaltrials |
| NCT00450970 | Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)(SPERA) | terminated | Phase 3 | 344 | AgennixINDUSTRY | 1 | Aug 17, 2012 | clinicaltrials |
| NCT00388804 | External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | terminated | Phase 3 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00294437 | ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases | terminated | Phase 3 | 376 | Central European Cooperative Oncology GroupOTHER | 16 | May 1, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials